Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610572 | 0.86 | KMT2A (0.47) | PSMB1PSMB5TDP1MEN1KMT2A | |
| SCHEMBL26312618 | 0.82 | HRH3 (0.40) | SLC2A1PSMB1PSMB5TDP1HRH3 | |
| SCHEMBL26312614 | 0.82 | HRH3 (0.37) | SLC2A1PSMB1PSMB5TDP1HRH3 | |
| SCHEMBL419937 | 0.82 | THRB (0.41) | TDP1HTTCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13888299 | 0.77 | CA12 (0.50) | ADRB2MEN1KMT2AGAA | |
| SCHEMBL16364692 | 0.77 | SLC2A1 (0.60) | SLC2A1 | |
| SCHEMBL720020 | 0.77 | DRD2 (0.48) | MEN1KMT2AHTT | |
| SCHEMBL11788154 | 0.77 | SMN1; SMN2 (0.47) | TDP1KMT2ACHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8285038 | 0.77 | SLC2A1 (0.51) | SLC2A1 | |
| SCHEMBL13888325 | 0.77 | TDP1 (0.48) | TDP1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524977-B2 | Process for producing fluoroalkanesulfonamide derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7524977-B2 | Process for producing fluoroalkanesulfonamide derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20080058538-A1 | Process for producing fluoroalkanesulfonamide derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20080058538-A1 | Process for producing fluoroalkanesulfonamide derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058538-A1 | Process for producing fluoroalkanesulfonamide derivatives | AFF1, AFF2, RER1 | SLC2A1 4453/4885PSMB1 3493/4885PSMB5 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.